No label defined (Q30524)
Jump to navigation
Jump to search
No description defined
- Doxycycline prophylaxis for the prevention of sexually transmitted infections: A systematic review and meta-analysis of randomized controlled trials.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
To investigate the effects of doxycycline pre- and post-exposure prophylaxis (doxy-PrEP/PEP) on bacterial sexually transmitted infections (STIs) by conducting a systematic review and meta-analysis. (English)
OBJECTIVES (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
PubMed, Embase, and CENTRAL were searched for randomized controlled trials (RCTs), including ongoing studies published until November 7, 2023. (English)
METHODS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Our primary endpoint was the incidence of bacterial STIs measured as the number of visits with an STI per total number of visits. (English)
METHODS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Random-effects model was used to estimate pooled effect sizes. (English)
METHODS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
The study was registered with PROSPERO, CRD42023478486. (English)
METHODS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
We identified six eligible studies containing data from seven articles and four conference abstracts, enrolling men who have sex with men (MSM), transgender women (TGW), and cisgender women (CGW). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
The pooled analysis of 1,766 participants with 602 newly diagnosed STIs showed a 56% decrease in the overall STI incidence using doxy-PrEP/PEP (RR = 0.44; 95% CI: 0.30-0.65; I<sup>2</sup> = 73%). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
For doxy-PEP, including MSM and TGW only, the RR observed for overall STI incidence was 0.40 (95% CI: 0.28-0.57; I² = 37%), 0.19 (95% CI: 0.08-0.44; I² = 39%) for chlamydia, 0.23 (0.14-0.36; I² = 0%) for syphilis and 0.55 (95% CI: 0.34-0.87; I² = 41%) for gonorrhea. (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
No serious adverse events were reported in the studies. (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
The certainty of evidence regarding the efficacy of doxy-PEP among MSM and TGW was graded as high. (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Doxy-PEP significantly reduces the number of new cases of chlamydia and syphilis and is potentially effective against gonorrhea, influenced by local resistance patterns. (English)
CONCLUSION (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Thus, it is a promising tool in the prevention of bacterial STIs among MSM and TGW. (English)
CONCLUSION (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Fanni Adél (English)
Meznerics (English)
FA
Kende (English)
Lőrincz (English)
K
Lajos Vince (English)
Kemény (English)
LV
Anna (English)
Walter (English)
A
Alzahra Ahmed (English)
Mohammed (English)
AA
Norbert (English)
Kiss (English)
N
23 October 2024
2 October 2024
Declarations of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (English)